Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Geographic Focus: China – Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – China In-Depth | China | 2023
The launch of several novel therapies, as well as multiple label expansions of existing drugs, will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) / chronic lymphocytic leukemia (CLL) market in China over the next 10 years. Rituximab (Roche’s MabThera, biosimilars) will continue to dominate the market owing to its favorable and well-established clinical profile, particularly as part of the R-CHOP chemotherapy regimen. Other key therapies expected to boost market growth include the CAR T-cell therapies (Yescarta [Fosun Pharma], Carteyva [JW Therapeutics], CNCT-19 [Juventas Cell Therapy], and IM-19 [Beijing Immunochina]), BTK inhibitors (Brukinsa [BeiGene], Imbruvica [Jansen / AbbVie], orelabrutinib [InnoCare], and pirtobrutinib [Loxo Oncology / Eli Lilly]), bispecific antibodies (glofitamab [Roche] and epcoritamab [Genmab]), ADCs (Polivy [Roche]), and EZH2 inhibitors (Tazverik [Epizyme]). In addition, combinations incorporating Imbruvica (Janssen / AbbVie), Calquence (AstraZeneca), and Venclexta (AbbVie / Roche) will enter the CLL market, resulting in a shift from conventional chemotherapy and rituximab-based regimens. This report provides a comprehensive analysis of NHL patient populations, current disease management, lingering unmet needs, and the clinical and commercial potential of current and emerging drugs.
Questions answered
- How large is China’s drug-treatable NHL population, and how will drug-treatment rates change during the forecast period?
- Which are the most commercially relevant drugs in China’s NHL market and why?
- What are interviewed experts’ insights into current treatment options?
- What are the key unmet needs in the management of NHL in China?
- What are the key market access considerations, and how will they impact the uptake of emerging therapies for NHL in China?
- What are the key drivers and constraints in this market, and how will the market evolve over the forecast period?
Content highlights
Release date: December 2023
Geography: China
Primary research: Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 75 hematologist-oncologists
Epidemiology: Diagnosed incidence of NHL in urban versus rural China, clinically relevant and market-relevant drug-treatable populations
Forecast: 10-year, annualized, drug-level sales and patient share of key NHL therapies through 2032, based on primary and secondary market research to formulate bottom-up assumptions
Emerging therapies: Phase 3 / PR: 10+ drugs; Phase 2: 15+ drugs; coverage of select Phase 1 products
Product description
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific access and reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
Table of contents
- Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia - Geographic Focus: China - Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia - China In-Depth | China | 2023
- China-In-Depth Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia - December 2023
- Executive Summary Deck_China In-Depth - 2023
- China-In-Depth Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia - Market Forecast Assumptions December 2023
- China In-Depth Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia - Market Forecast Dashboard December 2023
Karan Verma, M.Sc., is a lead healthcare research and data analyst on the China In-Depth team at Clarivate. He is involved in primary and secondary market research to create syndicated landscape and forecast content and provide Chinese market-specific insights in various therapy areas, including CAR T-cell therapies, prostate cancer, hepatocellular carcinoma, multiple myeloma, non-Hodgkin’s lymphoma, migraine, type 2 diabetes, and multiple sclerosis. He has expertise in market forecasting, competitive intelligence, benchmarking, and brand performance analytics. He obtained his M.Sc. in biomedical engineering from the University of Warwick in Coventry, United Kingdom, and a B.E. in biomedical engineering from Maharshi Dayanand University in Haryana, India.
Harinder Kumar, B.D.S., M.P.H., is an associate epidemiologist at Clarivate. His areas of interest are cancer and psychiatric epidemiology. Previously, Dr. Kumar worked with the government of Punjab, National Health Mission, India. He received his M.P.H. from the Tata Institute of Social Sciences in Mumbai. He holds a B.D.S. in dentistry from the National Dental College and Hospital in Punjab.